GlobalData: Injectable drugs and their packaging requirements provide ample opportunities for packaging firms to supply big pharmaceutical companies, given volume of vaccines, including latest omicron boosters and rising number of biologics

Sample article from our Packaging Industry

August 26, 2022 (press release) –

Injectable drugs and their packaging requirements are providing ample opportunities for packaging firms to supply big pharmaceutical companies, given the volume of vaccines, including the latest Omicron boosters required to tackle the COVID-19 pandemic, and the rising number of biologics, says GlobalData, a leading data and analytics company.

GlobalData’s report, ‘Contract Injectable Packaging Trends in the Bio/Pharma Industry’, reveals that there was an increase in approvals of injectable drugs from 2020 to 2021. The FDA and EMA generally approve more injectable drugs developed by large (market cap $10–100 billion) and mega cap (market cap >$100 billion) pharma companies than by smaller companies with market caps below $10 billion. Non-injectable approvals tend to have more small and mid cap sponsors as a proportion. This is because injectables – such as vaccines and monoclonal antibodies – are more complex than oral solid dose drugs – such as tablets – and so tend to be developed by larger companies with deeper pockets.

Adam Bradbury, Pharma Analyst at GlobalData, comments: “For injectable drugs, the FDA’s New Drug Application (NDA) approvals were relatively high in 2021 for small cap and mega cap drug sponsors. The number of approved injectable drugs sponsored by small, large, and mega cap companies increased since 2020.”

Bradbury continues: “The trend of small cap approvals increasing is potentially advantageous to contract manufacturing organisations (CMOs), given that historically their clients are more likely to be smaller companies that are unable to invest in their own facilities or enhance their own capabilities.”

The outsourcing propensity (the percentage of approved drugs for which a pharma sponsor company outsources manufacturing) is influenced greatly by the sponsor’s market cap and ability to acquire capabilities to package rather than outsourcing the task to a contractor. Innovative injectable products are more frequently sponsored by large and mega cap pharma companies than non-injectable or generic approvals.

Bradbury concludes: “Certain innovative products like cell and gene therapies have a limited pool of staff and expertise that can engage with their production; large CMOs have been acquiring these capabilities in recent years and, again, large and mega cap sponsors will require these services.”

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order packaging industry coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again.